A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study

• Published in: Journal of Korean medical science Vol. 28; no. 11; pp. 1609 - 1614
• Main Authors: Kim, Ung, Lee, Chan-Hee, Jo, Jung-Hwan, Lee, Hyun-Wook, Choi, Yoon-Jung, Son, Jang-Won, Lee, Sang-Hee, Park, Jong-Seon, Shin, Dong-Gu, Kim, Young-Jo, Jeong, Myung-Ho, Cho, Myung-Chan, Bae, Jang-Ho, Lee, Jae-Hwan, Kang, Tae-Soo, Jung, Kyung-Tae, Jung, Kyung-Ho, Lee, Seung-Wook, Cho, Jang-Hyun, Kim, Won, Hur, Seung-Ho, Kim, Ki-Sik, Park, Heon-Sik, Kim, Moo-Hyun, Hwang, Jin-Yong, Kim, Doo-Il, Kim, Tae-Ik
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Academy of Medical Sciences 01.11.2013; 대한의학회
• Subjects: Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - therapeutic use; Coronary Artery Disease - drug therapy; Coronary Artery Disease - mortality; Coronary Restenosis - prevention & control; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - therapeutic use; Male; Middle Aged; Original; Paclitaxel - administration & dosage; Paclitaxel - therapeutic use; Percutaneous Coronary Intervention - methods; Prospective Studies; Sirolimus - administration & dosage; Sirolimus - analogs & derivatives; Sirolimus - therapeutic use; Thrombosis; Treatment Outcome; 의학일반; Everolimus-Eluting Stent; Paclitaxel-Eluting Stent
• ISSN: 1011-8934; 1598-6357; 1598-6357
• DOI: 10.3346/jkms.2013.28.11.1609

We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) groups. The primary end-point was ischemia-driven target vessel revascularization (TVR) at 2 yr after intervention, and the secondary end-point was a major adverse cardiac event (MACE), such as death, myocardial infarction (MI), target lesion revascularization (TLR), TVR or stent thrombosis. A total of 850 patients with 1,039 lesions was randomized to the EES (n=425) and PES (n=425) groups. Ischemic-driven TVR at 2 yr was 3.8% in the PES and 1.2% in the EES group (P for non-inferiority=0.021). MACE rates were significantly different; 5.6% in PES and 2.5% in EES (P = 0.027). Rates of MI (0.8% in PES vs 0.2% in EES, P = 0.308), all deaths (1.5% in PES vs 1.2% in EES, P = 0.739) and stent thrombosis (0.3% in PES vs 0.7% in EES, P = 0.325) were similar. The clinical outcomes of EES are superior to PES, mainly due to a reduction in the rate of ischemia-driven TVR.